Century Therapeutics (IPSC) EBT (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of EBT data on file, last reported at -$21.7 million in Q1 2026.

• EBT for Q1 2026 came in at -$21.7 million, down 128.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.2 million (down 387.08% YoY), and the FY2025 annual result was $44000.0, up 100.04% from the prior year.
• EBT declined to -$21.7 million in Q1 2026 per IPSC's latest filing, from -$9.5 million in the prior quarter.
• Over five years, EBT peaked at $76.6 million in Q1 2025 and troughed at -$40.3 million in Q4 2023.
• A 5-year average of -$24.2 million and a median of -$31.2 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2025 and 2026: EBT surged 372.83% in 2025, then tumbled 128.3% in 2026.
• A 5-year view of EBT shows it stood at -$31.6 million in 2022, then fell by 27.23% to -$40.3 million in 2023, then advanced by 14.83% to -$34.3 million in 2024, then soared by 72.16% to -$9.5 million in 2025, then sank by 126.93% to -$21.7 million in 2026.
• Business Quant data shows IPSC's EBT at -$21.7 million in Q1 2026, -$9.5 million in Q4 2025, and -$34.4 million in Q3 2025.